106 related articles for article (PubMed ID: 9154972)
1. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
Victor F; Brown TJ; Campanale K; Heinz BA; Shipley LA; Su KS; Tang J; Vance LM; Spitzer WA
J Med Chem; 1997 May; 40(10):1511-8. PubMed ID: 9154972
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
Victor F; Loncharich R; Tang J; Spitzer WA
J Med Chem; 1997 Oct; 40(21):3478-83. PubMed ID: 9341923
[TBL] [Abstract][Full Text] [Related]
3. Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice.
Tebbe MJ; Spitzer WA; Victor F; Miller SC; Lee CC; Sattelberg TR; McKinney E; Tang JC
J Med Chem; 1997 Nov; 40(24):3937-46. PubMed ID: 9397174
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).
Chan JH; Chamberlain SD; Biron KK; Davis MG; Harvey RJ; Selleseth DW; Dornsife RE; Dark EH; Frick LW; Townsend LB; Drach JC; Koszalka GW
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):101-23. PubMed ID: 10772705
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 1-substitutes-5(6)-nitrobenzimidazoles as potential antiviral compounds.
Adams DR; Martul R
Acta Cient Venez; 1990; 41(2):88-92. PubMed ID: 1966927
[TBL] [Abstract][Full Text] [Related]
6. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.
Heinz BA; Vance LM
J Virol; 1995 Jul; 69(7):4189-97. PubMed ID: 7769678
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication.
Nikolaeva L; Galabov AS
Acta Virol; 1995 Dec; 39(5-6):235-41. PubMed ID: 8722291
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.
Yu KL; Sin N; Civiello RL; Wang XA; Combrink KD; Gulgeze HB; Venables BL; Wright JJ; Dalterio RA; Zadjura L; Marino A; Dando S; D'Arienzo C; Kadow KF; Cianci CW; Li Z; Clarke J; Genovesi EV; Medina I; Lamb L; Colonno RJ; Yang Z; Krystal M; Meanwell NA
Bioorg Med Chem Lett; 2007 Feb; 17(4):895-901. PubMed ID: 17169560
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.
Sin N; Venables BL; Combrink KD; Gulgeze HB; Yu KL; Civiello RL; Thuring J; Wang XA; Yang Z; Zadjura L; Marino A; Kadow KF; Cianci CW; Clarke J; Genovesi EV; Medina I; Lamb L; Krystal M; Meanwell NA
Bioorg Med Chem Lett; 2009 Aug; 19(16):4857-62. PubMed ID: 19596574
[TBL] [Abstract][Full Text] [Related]
10. Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication.
Stratford RE; Clay MP; Heinz BA; Kuhfeld MT; Osborne SJ; Phillips DL; Sweetana SA; Tebbe MJ; Vasudevan V; Zornes LL; Lindstrom TD
J Pharm Sci; 1999 Aug; 88(8):747-53. PubMed ID: 10430536
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
Arita M; Kojima H; Nagano T; Okabe T; Wakita T; Shimizu H
J Virol; 2011 Mar; 85(5):2364-72. PubMed ID: 21177810
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of the synergistic antienteroviral combination of enviroxime and disoxaril.
Nikolaeva L; Galabov AS
Acta Virol; 1999 Aug; 43(4):263-5. PubMed ID: 10749374
[TBL] [Abstract][Full Text] [Related]
13. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.
Arita M; Takebe Y; Wakita T; Shimizu H
J Gen Virol; 2010 Nov; 91(Pt 11):2734-44. PubMed ID: 20660150
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity and molecular features of benzimidazoles.
O'Sullivan DG; Ludlow C; Pantic D; Wallis AK
Antimicrob Agents Chemother (Bethesda); 1969; 9():153-9. PubMed ID: 4319306
[No Abstract] [Full Text] [Related]
15. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
De Palma AM; Thibaut HJ; van der Linden L; Lanke K; Heggermont W; Ireland S; Andrews R; Arimilli M; Al-Tel TH; De Clercq E; van Kuppeveld F; Neyts J
Antimicrob Agents Chemother; 2009 May; 53(5):1850-7. PubMed ID: 19237651
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
Zou R; Drach JC; Townsend LB
J Med Chem; 1997 Feb; 40(5):802-10. PubMed ID: 9057867
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
Xue F; Luo X; Ye C; Ye W; Wang Y
Bioorg Med Chem; 2011 Apr; 19(8):2641-9. PubMed ID: 21441033
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antiviral activity of certain 5'-modified analogs of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.
Gudmundsson KS; Drach JC; Wotring LL; Townsend LB
J Med Chem; 1997 Feb; 40(5):785-93. PubMed ID: 9057865
[TBL] [Abstract][Full Text] [Related]
19. The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice.
Tebbe MJ; Jensen CB; Spitzer WA; Franklin RB; George MC; Phillips DL
Antiviral Res; 1999 May; 42(1):25-33. PubMed ID: 10333140
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives.
Cheng J; Xie J; Luo X
Bioorg Med Chem Lett; 2005 Jan; 15(2):267-9. PubMed ID: 15603937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
